PDCD1 and cancer: Immune checkpoint inhibitors (ICIs) therapy targeting cytotoxic T lymphocyte antigen 4 (CTLA4) or programmed cell death-1 (PD-1) and its ligand PD-L1 has become the backbone of treatment for many cancers (1–3).